Leadartis announces its partnership in the TERET project.


Leadartis is proud to announce its participation as a partner in the TERET project (New Treatments for Degenerative Retina Diseases) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS of the society program. The MINECO’s participation demonstrates its support of Leadartis technology research and main objectives.

Leadartis reports its business strategy at BioSpain 2014


Leadartis has participated in BioSpain 2014 recently held in Santiago de Compostela (November 24-26th). BioSpain was chosen to present our business to the sector since is the most important biotechnology event in Spain and one of the most important internationally.

Leadartis to present its business at BioSpain 2014 on September 24th, 2014


Madrid (September 3rd). Leadartis, a privately held biotechnology company, is pleased to announce is participation at the BioSpain 2014 international biotechnology conference to be held in Santiago de Compostela (Spain) in September, 24th-26th, 2014

Leadartis announces the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board


Madrid (September 4th, 2014). Leadartis, a privately held biotechnology company, is pleased to announce the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board (SAB). Dr. Sanchez-Madrid together with the outstanding scientists and drug development professionals: Dr. L. Alvarez-Vallina, Dr. P. Kristensen, Dr. I. Melero and Dr. L.

Leadartis reports an efficient method for production of Trimerbody® molecules in Pichia Pastoris


In collaboration with prestigious academic institutions, LeadArtis´scientists demonstrated that single-chain fragment variable (scFv)-based N-terminal Trimerbody® molecules can be efficiently produced in the methylotrophic yeast Pichia pastoris (P. pastoris) in a trimeric fully functional active form. The yield of scFv-based N-terminal Trimerbody® molecules expressed in P. pastoris was about 20-fold higher than in mammalian cells. New marketed therapeutic proteins produced in Pichia evidence the rising interest of P.

LeadArtis announces the appointment of Dr. Juan J. Perez Villar as CEO.


In his new position, Juan will be responsible for raising investment capital, providing strategic leadership and overseeing operations for the Company. Juan brings more than 18 years of experience in the sector having previously served as Business Development Partner at Biolty (Madrid, Spain), prior to that Juan was Director of the industrial affairs department at the CEU University (Valencia, Spain) and head of oncology group at Astellas/Agensys (Santa Monica, CA, USA) and Bristol Myers Squibb (Princeton, NJ, USA). Juan earned a M.S. in biochemistry and a Ph.D.

LeadArtis announces financing and secures investors support.


Current investors of LeadArtis and others have confirmed the release of additional funding to the company, which will enable acceleration of the development of the Trimerbody® protein engineering platform and drug candidates. The investor syndicate composed of three investment organizations with a strong biotech record continues to express strong confidence in LeadArtis platform and portfolio of new promising drug candidates.

LeadArtis will join and contribute to the IACT project of the 7th European Framework programme.


European Framework programmes (FPs) are the European Union’s main instrument for funding European Medical Research. They support the creation of multidisciplinary networks designed to promote the collaboration of health-related industries and integrate European-wide research, “as well as build a ‘critical mass’ of expertise and excellence”.

LeadArtis participates in the IACT Kick-off meeting


The IACT Kick-off meeting took place November 12, 2013 in Frankfurt, Germany. Representatives of all partners, including all general assembly members and representatives of management team participated in the meeting.

Syndicate content

Latest News

Clave Capital invests in Leadartis in a funding round of more than €1,600,000

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its...

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis

The entry of funds into leadartis' shareholding is part of a round of financing closed by...

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research